BioSpace News Archive

89bio, Inc. announced that data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis were published online in the New England Journal of Medicine.

Vir Biotechnology, Inc. announced new data from its robust hepatitis B and D virus portfolio that were presented at the EASL™ Congress.

Arrowhead Pharmaceuticals Inc. presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.

A new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with risk factors for coronary artery disease and high cholesterol, particularly those with diabetes, should be treated with a cholesterol-lowering drug.

Rallybio Corporation reported data from the Phase 1b proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of fetal and neonatal alloimmune thrombocytopenia.

Novo Nordisk announced that data from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly insulin icodec, which were presented at the 83rd Annual Scientific Sessions of the American Diabetes Association, showed the studies met their primary endpoints and insulin icodec provided similar glucose-lowering effects while reducing injections from seven to one per week compared with once-daily basal insulin1-2.

Inventiva announced that the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” has been selected for poster presentation during the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 202 in San Diego, United States.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence of benefit on weight beyond treatment.

89bio, Inc. announced that the previously reported positive data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia were published online in Nature Medicine.

At the Society of Nuclear Medicine and Molecular Imaging 2023 annual meeting, GE HealthCare is proud to showcase new, innovative technologies and diagnostics that enable personalized medicine and precision care to help clinicians improve patient outcomes around the world.